Ascent Pharmaceuticals APG-1252 won an oral report at the 2021 World Lung Cancer Conference, revealing the potential of combining osimertinib in the treatment of drug-resistant non-small cell lung cancer

As a leading biomedical company dedicated to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases, Yasheng Pharmaceutical (6855.

WCLC is the world's largest multidisciplinary oncology conference dedicated to lung cancer and other thoracic malignancies organized by the International Association for the Study of Lung Cancer (IASLC), focusing on the most cutting-edge scientific research and clinical progress in this field

APG-1252 is a new type of Bcl-2/Bcl-xL dual-target inhibitor independently developed by Yasheng Pharmaceutical, which can repair cell apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins

The key information of APG-1252's small oral report on this WCLC is as follows:

Phase Ib study of Pelcitoclax (APG-1252) combined with osimertinib in the treatment of EGFR TKI-resistant non-small cell lung cancer (NSCLC) patients

Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC

Abstract number

MA02.

Special

New drugs and targeted therapies

Novel Therapeutics and Targeted Therapies

time

China Time: September 9th 00:05 – 00:10

Mountain time: September 8th 10:05 – 10:10

Key Information

This is a single-arm, multi-center, phase Ib study of APG-1252 combined with osimertinib in the treatment of patients with advanced EGFR mutation-positive NSCLC, including dose exploration and dose expansion

As of June 24, 2021, 56 patients have been included in the study

• During the dose exploration phase, 1 case of PR was observed in 11 evaluable patients

• Dose expansion cohort 1, 3 cases of PR (2 cases of osimertinib resistance) and 13 cases of SD were observed in 20 evaluable patients, with ORR of 15% and DCR of 80%

• Dose expansion cohort two.

• In terms of safety: During the dose exploration phase, one case of DLT with grade 4 thrombocytopenia occurred at 240 mg of APG-1252

in conclusion

APG-1252 combined with osimertinib is safe and well tolerated

Professor Zhang Li

Sun Yat-sen University Cancer Center

Although osimertinib has become the first-line treatment of choice for patients with EGFR-mutant NSCLC, there is currently no effective treatment plan for patients with drug resistance

Dr.

There is still a huge unmet clinical need for the treatment of NSCLC, especially for patients with EGFR TKI resistance, there is still a lack of effective treatment methods

About Yasheng Pharmaceutical (6855.

Ascent Pharmaceuticals has a self-constructed protein-protein interaction targeted drug design platform, and is at the forefront of new drug development in the apoptosis pathway in the world
.
The company has established a pipeline of 8 class 1 small molecule new drug products that have entered the clinical development stage, including inhibitors that inhibit key proteins in the apoptosis pathway such as Bcl-2, IAP or MDM2-p53; a new generation of drugs that have emerged in cancer treatment Inhibitors of kinase mutants, etc.
, are the only innovative company in the world that has clinically developed varieties in the field of key proteins in the apoptosis pathway
.
The company is currently conducting more than 40 phase I/II clinical trials in China, the United States, Australia and Europe
.
The company has undertaken a number of major national science and technology projects, including 5 special projects for "Major New Drug Development", including 1 "Enterprise Innovative Drug Incubation Base" and 4 "Innovative Drug Research and Development", and another special project for "Prevention and Control of Major Infectious Diseases".

.
The core variety HQP1351, which is used to treat drug-resistant chronic myeloid leukemia, has been submitted for new drug marketing applications in China and has been included in the priority review and breakthrough therapy varieties
.
This variety has also obtained the U.
S.
FDA's fast track review and orphan drug certification
.
Up to now, the company has 4 new drugs under development that have obtained 12 FDA orphan drug qualification certifications
.

Relying on strong R&D capabilities, Yasheng Pharmaceuticals has deployed intellectual property rights worldwide, and has cooperated with leading biotechnology and pharmaceutical companies such as UNITY, MD Anderson, Mayo Medical Center, Dana-Farber Cancer Institute, Merck, AstraZeneca, etc.
Companies and academic institutions have reached a global partnership
.
The company has established an international talent team with rich experience in original innovative drug research and development and clinical development.
At the same time, the company is building a late-stage commercial production and marketing team with high standards
.
Yasheng Pharmaceutical will continue to improve its research and development capabilities, accelerate the progress of the clinical development of the company's product pipeline, and truly implement the mission of "solving the unmet clinical needs of patients in China and even the world" to benefit more patients
.

Forward-looking statement

The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article
.
Except as required by law, we have no obligation to update or publicly revise any forward-looking statements and unexpected events after the date of forward-looking statements, regardless of whether new information, future events or other circumstances appear
.
Please read this article carefully and understand that our actual future results or performance may differ materially from expectations
.
All statements in this article are made on the date of publication of this article and may change due to future developments
.